RECRUITING

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients with High-Risk Prostate Cancer

Talk to us

Conditions

Prostate Cancergenetic testing

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.

Official Title

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients with High-Risk Prostate Cancer

Quick Facts

Study Start:2025-01-01
Study Completion:2026-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05958082

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Men, age greater than or equal to 18 years of age.
  2. 2. Men who racially identify as black or multiracial including black
  3. 3. Diagnosis of prostate cancer of any histology.
  4. 4. Must meet NCCN guidelines for germline testing
  5. 1. Men with very low, low or intermediate risk prostate per NCCN guidelines with a positive family history or intraductal histology. Family history here is considered significant if the patient has:
  6. * a first degree relative with prostate cancer or more than one first/second degree relative with prostate cancer, or
  7. * ≥3 cancers on same side of family, especially diagnoses ≤50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, or urothelial cancer
  8. 2. Men with high-risk, very-high risk (per NCCN definitions of risk groups), lymph node positive, or metastatic prostate cancer independent of family history of histology.
  1. 1. Have had prior germline testing.
  2. 2. Have somatic genetic testing that is positive for a possible germline variant.

Contacts and Locations

Study Contact

Clara Hwang, MD
CONTACT
313-556-8830
chwang2@hfhs.org
Karthik Subramanian, MS
CONTACT
313-401-9815
ksubram3@hfhs.org

Study Locations (Sites)

Henry Ford Cancer Pavilion
Detroit, Michigan, 48202
United States

Collaborators and Investigators

Sponsor: Henry Ford Health System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-01
Study Completion Date2026-06

Study Record Updates

Study Start Date2025-01-01
Study Completion Date2026-06

Terms related to this study

Keywords Provided by Researchers

  • genetic testing

Additional Relevant MeSH Terms

  • Prostate Cancer